Sarepta and catalent expand strategic manufacturing partnership with commercial supply agreement for duchenne muscular dystrophy gene therapy candidate

Somerset, n.j. & cambridge, mass.--( business wire )--catalent, inc. (nyse:ctlt), the leader in enabling the development and supply of better treatments for patients worldwide, and sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today announced the signing of a commercial supply agreement for catalent to manufacture delandistrogene moxeparvovec (srp-9001), sarepta's most advanced gene therapy candidate for the treatment of duchenne muscular dystrophy (dmd). the agreement also structures how catalent may support multiple gene therapy candidates in sarepta's pipeline for limb-girdle muscular dystrophy (lgmd).
SRPT Ratings Summary
SRPT Quant Ranking